Characteristics of 21 patients with rare variant lymphomas, categorised as “H5” for the analysis
| Histology | Number of cases | Age at diagnosis (years) | Proportion of males | Proportion with extraorbital spread at diagnosis | Proportion with extraorbital spread at any time | Proportion with lymphoma related death |
| MCL | 6 | 66 (median) | 4/6 (67%) | 5/6 (83%) | 6/6 (100%) | 1/6 (17%) |
| CLL | 5 | 60 (median) | 3/5 (60%) | 4/5 (80%) | 5/5 (100%) | 5/5 (100%) |
| BPLL | 3 | 3, 3, 9 | 3/3 | 2/3 (67%) | 3/3 (100%) | 1/3 (33%) |
| TPLL | 1 | 3 | 1/1 | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| MF | 3 | 58, 79, 81 | 2/3 (67%) | 3/3 (100%) | 3/3 (100%) | 1/3 (33%) |
| PM | 2 | 59, 74 | 2/2 | 2/2 (100%) | 2/2 (100%) | 1/2 (50%) |
| ATL | 1 | 17 | 1/1 | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
MCL = mantle cell lymphoma; CLL = chronic lymphocytic lymphoma; BPLL = B precursor lymphoblastic leukaemia/lymphoma; TPLL = T precursor lymphoblastic leukaemia/lymphoma; MF = mycosis fungoides; PM = plasma cell myeloma; ATL = angiocentric T cell lymphoma.